US2022202777A1PendingUtilityA1

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

79
Assignee: ALLERGAN INCPriority: Oct 26, 2011Filed: Apr 13, 2021Published: Jun 30, 2022
Est. expiryOct 26, 2031(~5.2 yrs left)· nominal 20-yr term from priority
Inventors:Richard L. BeardTien T. DuongJohn E. DonelloVeena ViswanathMichael E. Garst
C07K 5/06156A61K 31/197C07K 5/06147C07C 317/50C07K 5/06113C07C 323/60C07C 323/44A61P 27/00C07K 5/0606A61K 31/216A61P 29/00C07K 5/06017C07C 275/30C07D 233/64A61K 31/4045C07C 275/28C07D 209/20A61K 31/17A61K 31/417C07C 317/42C07D 209/18C07K 5/06052A61P 27/02Y02A50/30C07K 5/06034C07K 5/06A61P 43/00A61K 31/198C07C 323/59
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising a therapeutically effective amount of a compound having the following structure: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.

Join the waitlist — get patent alerts

Track US2022202777A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.